Received Jul 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Incomplete course of vaccination; This non-serious case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a 50-year-old female patient who did not receive HBV (Engerix B) for prophylaxis. Previously administered products included RECOMBIVAX (received on 14th June 2014). Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On an unknown date, the patient did not receive the 2nd dose of Engerix B. The patient experienced incomplete course of vaccination (Verbatim: Incomplete course of vaccination). The outcome of the incomplete course of vaccination was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-JUN-2025 The reporter called to ask they had a worker that received a Hepatitis B vaccine on twenty-fourteen (with a non-GlaxoSmithKline vaccine), and recently a ENGERIX-B on May twenty twenty-five. The reporter asked if they must administer a complete series for GlaxoSmithKline vaccine or when could they administer the third required dose for this patient. The reporter asked was there any advice on this. The vaccination date, vaccine detail and patient demographics were obtained in this call. No further information was obtained in this call. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter. Till the time of reporting, the patient did not receive the 2nd dose of Engerix B, which led to incomplete course of vaccination.
ENGERIX B